Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + fluorouracil + leucovorin + lenvatinib + tislelizumab
- Development stage
- Phase 2
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intra-arterial, Oral, Intravenous
01
Overview
Irinotecan liposome + 5-FU/LV + lenvatinib + tislelizumab is a multi-agent combination regimen under clinical investigation for the first-line treatment of unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma (ICC). The regimen combines regional and systemic therapies: hepatic arterial infusion chemotherapy (HAIC) using liposomal irinotecan (a topoisomerase I inhibitor), 5-fluorouracil (an antimetabolite), and leucovorin (a biochemical modulator); oral lenvatinib (a multi-target receptor tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR, RET, and KIT); and tislelizumab (a PD-1 immune checkpoint inhibitor). This approach aims to maximize local tumor control in the liver while providing systemic anti-angiogenic and immunotherapeutic effects. The regimen is currently being evaluated in a Phase 2 trial (NCT07646717) sponsored by Tianjin Medical University Cancer Institute and Hospital.
- Other names
- LPHAICHAIC + Lenvatinib + TislelizumabLPHAIC for ICC
02
Targets
TOP1 (DNA Topoisomerase I)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on irinotecan liposome + fluorouracil + leucovorin + lenvatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + fluorouracil + leucovorin + lenvatinib + tislelizumab.